- Home
- TALO vs IMCR Comparison
TALO vs IMCR Comparison
Compare TALO & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TALO
- IMCR
- Stock Information
- Founded
- TALO 2011
- IMCR 2008
- Country
- TALO United States
- IMCR United Kingdom
- Employees
- TALO N/A
- IMCR N/A
- Industry
- TALO Oil & Gas Production
- IMCR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TALO Energy
- IMCR Health Care
- Exchange
- TALO Nasdaq
- IMCR Nasdaq
- Market Cap
- TALO 1.6B
- IMCR 1.8B
- IPO Year
- TALO N/A
- IMCR 2021
- Fundamental
- Price
- TALO $9.64
- IMCR $33.81
- Analyst Decision
- TALO Buy
- IMCR Buy
- Analyst Count
- TALO 7
- IMCR 8
- Target Price
- TALO $14.29
- IMCR $57.00
- AVG Volume (30 Days)
- TALO 2.2M
- IMCR 270.5K
- Earning Date
- TALO 11-10-2025
- IMCR 11-05-2025
- Dividend Yield
- TALO N/A
- IMCR N/A
- EPS Growth
- TALO N/A
- IMCR N/A
- EPS
- TALO N/A
- IMCR N/A
- Revenue
- TALO $1,931,650,000.00
- IMCR $356,145,000.00
- Revenue This Year
- TALO N/A
- IMCR $31.83
- Revenue Next Year
- TALO N/A
- IMCR $8.50
- P/E Ratio
- TALO N/A
- IMCR N/A
- Revenue Growth
- TALO 10.70
- IMCR 26.78
- 52 Week Low
- TALO $6.23
- IMCR $23.15
- 52 Week High
- TALO $12.71
- IMCR $39.33
- Technical
- Relative Strength Index (RSI)
- TALO 58.00
- IMCR 46.61
- Support Level
- TALO $9.27
- IMCR $35.33
- Resistance Level
- TALO $9.90
- IMCR $36.76
- Average True Range (ATR)
- TALO 0.29
- IMCR 1.43
- MACD
- TALO -0.03
- IMCR 0.00
- Stochastic Oscillator
- TALO 52.45
- IMCR 30.79
About TALO Talos Energy Inc.
Talos Energy Inc is an independent oil and gas company predominantly involved in offshore exploration and production. The company has operations in the United States, the Gulf of Mexico, and offshore Mexico. The company's operating segments are; exploration and production of oil, natural gas and NGLs, and the CCS segment. The revenue is generated from the sale of oil, natural gas, and NGL quantities sold to purchasers.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.